Neural stem cell

HKBU invents nanostructure that stimulates growth of stem cells for Parkinson's disease treatment

Retrieved on: 
Friday, May 22, 2020
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Cloning, Developmental biology, Neural stem cell, Induced stem cells, Amniotic epithelial cell

HONG KONG, May 22, 2020 /PRNewswire/ -- Researchers from Hong Kong Baptist University (HKBU) have invented a nanostructure that can stimulate neural stem cells to differentiate into nerve cells.

Key Points: 
  • HONG KONG, May 22, 2020 /PRNewswire/ -- Researchers from Hong Kong Baptist University (HKBU) have invented a nanostructure that can stimulate neural stem cells to differentiate into nerve cells.
  • They found that the transplantation of these nerve cells into rats with Parkinson's disease progressively improved their symptoms, with the new cells replacing damaged nerve cells around the transplantation site.
  • This novel invention provides promising insights into stem cell therapies and offers hope of a new treatment for Parkinson's disease.
  • The chemicals used may stimulate the growth of cancer cells and increase the risk of developing tumours after transplantation to human body.

HKBU invents nanostructure that stimulates growth of stem cells for Parkinson's disease treatment

Retrieved on: 
Friday, May 22, 2020
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Cloning, Developmental biology, Neural stem cell, Induced stem cells, Amniotic epithelial cell

HONG KONG, May 21, 2020 /PRNewswire/ -- Researchers from Hong Kong Baptist University (HKBU) have invented a nanostructure that can stimulate neural stem cells to differentiate into nerve cells.

Key Points: 
  • HONG KONG, May 21, 2020 /PRNewswire/ -- Researchers from Hong Kong Baptist University (HKBU) have invented a nanostructure that can stimulate neural stem cells to differentiate into nerve cells.
  • They found that the transplantation of these nerve cells into rats with Parkinson's disease progressively improved their symptoms, with the new cells replacing damaged nerve cells around the transplantation site.
  • This novel invention provides promising insights into stem cell therapies and offers hope of a new treatment for Parkinson's disease.
  • The chemicals used may stimulate the growth of cancer cells and increase the risk of developing tumours after transplantation to human body.

AgeX Therapeutics to Collaborate with University of California, Irvine on Neural Stem Cell Research Program for Huntington’s Disease and Other Neurological Disorders

Retrieved on: 
Monday, February 3, 2020
Research, Seniors, Stem cells, Biotechnology, University, Pharmaceutical, Consumer, Health, Science, Education, Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Neural stem cell, AgeX Therapeutics

The initial focus will be on Huntingtons disease, while other potential targets may include Parkinsons, Alzheimers, and stroke.

Key Points: 
  • The initial focus will be on Huntingtons disease, while other potential targets may include Parkinsons, Alzheimers, and stroke.
  • Our goal is to have an improved neural stem cell production method ready within a year to move into clinical development, said Professor Thompson.
  • Neural stem cells may be very useful in other neurological disorders that are common in aging demographics, such as Parkinsons, Alzheimers and stroke.
  • AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging.

ReNeuron Presents Positive Data at the 27th Annual Congress of the European Society of Gene and Cell Therapy on Lead Cell Line

Retrieved on: 
Wednesday, October 23, 2019
Branches of biology, Biology, Life sciences, Stem cells, Stem-cell therapy, Stem-cell line, Mesenchymal stem cell, Cell therapy, Neural stem cell, Induced stem cells, Royan Institute

Dr. Steve Pells, Principal Investigator at ReNeuron, will present new data showing the phenotypic stability and scalability of a mesenchymal stem cell line derived from the Company's proprietary, conditionally immortalized, human neural stem cell line (CTX) following re-programming to a pluripotent state.

Key Points: 
  • Dr. Steve Pells, Principal Investigator at ReNeuron, will present new data showing the phenotypic stability and scalability of a mesenchymal stem cell line derived from the Company's proprietary, conditionally immortalized, human neural stem cell line (CTX) following re-programming to a pluripotent state.
  • Further, the mesenchymal stem cell lines generated can be grown at scale by virtue of the Company's conditional immortalization technology, enabling the efficient production of clinical-grade cell therapy candidates.
  • non-donor-specific) cell lines from any of the three primary germ cell layers which form during embryonic development.
  • ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs.

Neuralstem Announces Last Subject Enrolled in Phase 2 Clinical Trial Evaluating Human Neural Stem Cells in Chronic Stroke Patients

Retrieved on: 
Tuesday, September 24, 2019
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Life extension, Stem-cell therapy, Stroke, Neural stem cell, Placebo, Neuralstem, Inc.

NSI-566 is Neuralstem's lead stem cell therapy candidate, and has also been evaluated in clinical trials for patients with Amyotrophic Lateral Sclerosis and chronic spinal cord injury.

Key Points: 
  • NSI-566 is Neuralstem's lead stem cell therapy candidate, and has also been evaluated in clinical trials for patients with Amyotrophic Lateral Sclerosis and chronic spinal cord injury.
  • "Completing the subject enrollment in this Phase 2 study is an important clinical milestone for Neuralstem," said Dr. Ken Carter, Executive Chairman of Neuralstem.
  • The double-blind, placebo-controlled study enrolled 22 subjects that were randomized to one of two groups: a treatment group that received intracerebral administration of 72 million human neural stem cells or a sham surgery group.
  • Ischemic stroke, the most common type of stroke, occurs as a result of an obstruction within a blood vessel supplying blood to the brain.

Neuralstem Announces Publication of Results from Phase 1 Clinical Trial Evaluating Human Neural Stem Cells in Chronic Stroke Patients

Retrieved on: 
Monday, July 1, 2019
Branches of biology, Biology, Medicine, Stem cells, RTT, Stroke, Biotechnology, Neural stem cell, Ischemia, Immunosuppression, Thrombosis, Cerebrovascular disease

The manuscript, entitled 'Stable Intracerebral Transplantation of Neural Stem Cells for the Treatment of Paralysis Due to Ischemic Stroke,' summarizes the results of an open label trial performed at BaYi Brain Hospital in Beijing, China, with Principal Investigator Professor Xu Ruxiang.

Key Points: 
  • The manuscript, entitled 'Stable Intracerebral Transplantation of Neural Stem Cells for the Treatment of Paralysis Due to Ischemic Stroke,' summarizes the results of an open label trial performed at BaYi Brain Hospital in Beijing, China, with Principal Investigator Professor Xu Ruxiang.
  • Subjects were maintained on immunosuppressive drugs for 28 days following transplantation and were monitored for up to 24 months after surgery.
  • 'We are grateful to our collaborators at BaYi Brain Hospital and to the subjects who participated in the trial,' said Dr. Ken Carter, Executive Chairman of Neuralstem.
  • Ischemic stroke, the most common type of stroke, occurs as a result of an obstruction within a blood vessel supplying blood to the brain.

Stem Cell Line Shows Potential in Helping Recover Motor Function After a Stroke

Retrieved on: 
Wednesday, June 26, 2019
Branches of biology, Biology, Life sciences, Stem cells, Induced stem cells, Biotechnology, Cloning, Developmental biology, Stem-cell line, Stem-cell therapy, Neural stem cell

Cells appeared to survive long-term, and patients in the single-arm trial showed improvements in motor function following cell transplantation.

Key Points: 
  • Cells appeared to survive long-term, and patients in the single-arm trial showed improvements in motor function following cell transplantation.
  • This indicates the procedure is safe and may have potential to provide benefit to patients with motor deficits from stroke.
  • The patients were divided into three equal groups, with each group administered a different dose of the stem cell line.
  • RMF pursues its mission by producing its flagship World Stem Cell Summit, honouring leaders through the Stem Cell and Regenerative Medicine Action Awards, and promoting educational initiatives.

Neuralstem Announces Issuance of New Patent Covering Broad Therapeutic Use of Neural Stem Cells

Retrieved on: 
Thursday, May 16, 2019
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Induced stem cells, Cloning, Developmental biology, Neural stem cell, Amyotrophic lateral sclerosis, Stem-cell therapy, Neuralstem, Inc.

10,286,010, entitled "Methods of Treating Neurodegenerative Conditions" was issued on May 14, 2019, by the United States Patent and Trademark Office (USPTO).

Key Points: 
  • 10,286,010, entitled "Methods of Treating Neurodegenerative Conditions" was issued on May 14, 2019, by the United States Patent and Trademark Office (USPTO).
  • The patent covers the use of transplanted human neural stem cells for the treatment of neurodegeneration resulting from disease and injury.
  • "We are very pleased to have been awarded this patent," said Dr. Kenneth Carter, Ph.D, Executive Chairman of Neuralstem.
  • "It provides Neuralstem with broad protection for the use of our neural stem cells in the treatment of diseases such as stroke, traumatic brain injury, spinal cord injury, and ALS, and extends the scope and lifespan of our neural stem cell IP portfolio."

Strategic Development of Neural Stem & Progenitor Cell Products (2019 Study) - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 14, 2019
Health, Biotechnology, Clinical trials, Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Cloning, Developmental biology, Adult stem cell, Neural stem cell, Progenitor cell, Induced stem cells

The "Strategic Development of Neural Stem and Progenitor Cell Products" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Strategic Development of Neural Stem and Progenitor Cell Products" report has been added to ResearchAndMarkets.com's offering.
  • While the number of adult stem cell therapies entering clinical trials continues to expand, the development of neural stem cell therapies has been affected by barriers to entry that include patent restrictions, the complexity of neural stem cell applications, and burden of undertaking costly clinical trials.
  • Despite these limitations, dozens of companies are now pursuing preclinical and clinical programs utilizing neural stem and progenitor cells as therapeutic products.
  • The growth of stem cell research has exploded over the past decades, and the market for neural stem cell and progenitor cell products is also expanding.

Neural Stem & Progenitor Cell Products Market, 2019 - Current & Future Needs of the NSC Marketplace

Retrieved on: 
Friday, March 15, 2019
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Developmental biology, Cell biology, Cloning, Neural stem cell, Progenitor cell, NSPC, Miltenyi Biotec

DUBLIN, March 15, 2019 /PRNewswire/ -- The "Strategic Development of Neural Stem and Progenitor Cell Products" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 15, 2019 /PRNewswire/ -- The "Strategic Development of Neural Stem and Progenitor Cell Products" report has been added to ResearchAndMarkets.com's offering.
  • The growth of stem cell research has exploded over the past decades, and the market for neural stem cell and progenitor cell products is also expanding.
  • Claim this 211-page global strategic report to reveal the current and future needs of the NSC marketplace, outmaneuver your competition, and approach investors with specific and technical knowledge of the global market for neural stem cell and progenitor cell products.
  • Despite these limitations, dozens of companies are now pursuing preclinical and clinical programs utilizing neural stem and progenitor cells as therapeutic products.